you think AGEN's manufacturing issue will also show up on DNDN's doorstep? Admittedly DNDN's process is easier (therefore more easily reproducible), but it is autologous nonetheless.
Before I forget... for that pdf on Genvec's AdPEDF results: They present vision gain / loss in terms of letters, whereas others provide data by lines. I assume the latter is more difficult to achieve. However, is there a standard conversion of letters to lines? 3 letters per line?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.